Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Annette Hasenburg Prof., Dr, med
Annette Hasenburg Prof., Dr, med Advisory Board
Benjamin Anderson MD, FACS
Benjamin O. Anderson MD, FACS Advisory Board
Roger Stupp MD
Roger Stupp MD Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · May 30, 2019

Gastroesophageal Adenocarcinoma Not Improved With Rilotumumab and Panitumumab

European Journal of Cancer

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

European Journal of Cancer
FOLFOX Alone or Combined With Rilotumumab or Panitumumab as First-Line Treatment for Patients With Advanced Gastroesophageal Adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): A Randomised, Open-Label, Three-Arm Phase II Trial
Eur. J. Cancer 2019 May 23;115(xx)97-106, D Malka, E François, F Penault-Llorca, F Castan, O Bouché, J Bennouna, F Ghiringhelli, C Fouchardière, C Borg, E Samalin, JB Bachet, JL Raoul, L Miglianico, L Bengrine-Lefèvre, L Dahan, C Lecaille, T Aparicio, T Stanbury, H Perrier, A Cayre, P Laurent-Puig, S Gourgou, JF Emile, J Taïeb

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated